• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, September 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

Nanodiscs deliver personalized cancer therapy to immune system

Bioengineer by Bioengineer
December 26, 2016
in Science News
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

ANN ARBOR — Researchers at the University of Michigan have had initial success in mice using nanodiscs to deliver a customized therapeutic vaccine for the treatment of colon and melanoma cancer tumors.

"We are basically educating the immune system with these nanodiscs so that immune cells can attack cancer cells in a personalized manner," said James Moon, the John Gideon Searle assistant professor of pharmaceutical sciences and biomedical engineering.

Personalized immunotherapy is a fast-growing field of research in the fight against cancer.

The therapeutic cancer vaccine employs nanodiscs loaded with tumor neoantigens, which are unique mutations found in tumor cells. By generating T-cells that recognize these specific neoantigens, the technology targets cancer mutations and fights to eliminate cancer cells and prevent tumor growth.

Unlike preventive vaccinations, therapeutic cancer vaccines of this type are meant to kill established cancer cells.

"The idea is that these vaccine nanodiscs will trigger the immune system to fight the existing cancer cells in a personalized manner," Moon said.

The nanodisc technology was tested in mice with established melanoma and colon cancer tumors. After the vaccination, twenty-seven percent of T-cells in the blood of the mice in the study targeted the tumors.

When combined with immune checkpoint inhibitors, an existing technology that amplifies T-cell tumor-fighting responses, the nanodisc technology killed tumors within 10 days of treatment in the majority of the mice. After waiting 70 days, researchers then injected the same mice with the same tumor cells, and the tumors were rejected by the immune system and did not grow.

"This suggests the immune system 'remembered' the cancer cells for long-term immunity," said Rui Kuai, U-M doctoral student in pharmaceutical sciences and lead author of the study.

"The holy grail in cancer immunotherapy is to eradicate tumors and prevent future recurrence without systemic toxicity, and our studies have produced very promising results in mice," Moon said.

The technology is made of extremely small, synthetic high density lipoproteins measuring roughly 10 nanometers. By comparison, a human hair is 80,000 to 100,000 nanometers wide.

"It's a powerful vaccine technology that efficiently delivers vaccine components to the right cells in the right tissues. Better delivery translates to better T-cell responses and better efficacy," said study co-senior author Anna Schwendeman, U-M assistant professor of pharmacy.

The next step is to test the nanodisc technology in a larger group of larger animals, Moon said.

EVOQ Therapeutics, a new U-M spinoff biotech company, has been founded to translate these results to the clinic. Lukasz Ochyl, a doctoral student in pharmaceutical sciences, is also a co-author.

The study, "Designer vaccine nanodiscs for personalized cancer immunotherapy," is scheduled for advance online publication Dec. 26 on the Nature Materials website.

###

Media Contact

Laura Bailey
[email protected]
734-647-1848
@umich

http://www.umich.edu/

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

Transforming Secondary Aluminum Ash into Efficient Phase Change Materials

Transforming Secondary Aluminum Ash into Efficient Phase Change Materials

September 2, 2025

Protein Lipoylation: Key to Cancer Metabolic Therapy

September 2, 2025

Optimizing Personalized Learning Paths with Advanced Neural Networks

September 2, 2025

New Biomarkers for COVID-19 ARDS Identified Using AI

September 2, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    154 shares
    Share 62 Tweet 39
  • Molecules in Focus: Capturing the Timeless Dance of Particles

    143 shares
    Share 57 Tweet 36
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    117 shares
    Share 47 Tweet 29
  • Do people and monkeys see colors the same way?

    112 shares
    Share 45 Tweet 28

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Transforming Secondary Aluminum Ash into Efficient Phase Change Materials

Protein Lipoylation: Key to Cancer Metabolic Therapy

Optimizing Personalized Learning Paths with Advanced Neural Networks

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.